Quixotic Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 15-12-2024
- Paid Up Capital ₹ 0.74 M
as on 15-12-2024
- Company Age 22 Year, 21 Days
- Last Filing with ROC 31 Mar 2024
- Revenue 0.32%
(FY 2022)
- Profit -23.45%
(FY 2022)
- Ebitda -21.56%
(FY 2022)
- Net Worth 24.84%
(FY 2022)
- Total Assets 21.16%
(FY 2022)
About Quixotic Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.74 M, as per Ministry of Corporate Affairs (MCA) records.
Rajesh Shrivastava, Sanjeev Kumar, Sanjay Dhir, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232PB2002PTC025609
- Company No.
025609
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Nov 2002
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Rupnagar, Punjab, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Quixotic Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Shrivastava  | Director | 13-Aug-2019 | Current |
| Sanjeev Kumar | Director | 29-Nov-2002 | Current |
| Sanjay Dhir | Director | 01-Feb-2018 | Current |
| Hitesh Oswal | Director | 01-Feb-2018 | Current |
| Sudhakar | Director | 11-Sep-2023 | Current |
Financial Performance and Corporate Structure Insights of Quixotic Pharma.
Quixotic Pharma Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 0.32% increase. The company also saw a substantial fall in profitability, with a 23.45% decrease in profit. The company's net worth Soared by an impressive increase of 24.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Quixotic Pharma?
In 2022, Quixotic Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Preet Remedies LimitedActive 19 years 10 monthsRajesh Shrivastava, Sanjeev Kumar and 2 more are mutual person
Ultra Chiron Pharmaceuticals Pvt LtdActive 31 years 5 monthsRajesh Shrivastava, Sanjeev Kumar and 1 more are mutual person
Oasis Pharma And Phytomolecules Private LimitedActive 17 years 7 monthsSanjeev Kumar and Sanjay Dhir are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Quixotic Pharma?
Quixotic Pharma has a workforce of 2 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Quixotic Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Quixotic Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
